

Financial Results for the year ended March 31, 2023

May 11, 2023



1. Action to implement management that is conscious of cost of capital and stock price

2. Financial results for the year ended March 31, 2023

3. Forecast for the year ending March 31, 2024

Action to implement management that is conscious of cost of capital and stock price



Analysis of current situation

- Improving Price-to-Book Ratio (PBR) is an important management challenge.
 - Announced in April 2022 an ROE target (8%+ in FY25) that is cognizant of our Cost of Equity.
 - ROE was in the 7% range in FY21 and FY22. In FY23, ROE is expected to be in 5% range due to the business cycle and other factors.
 - The reasons for the low PBR are due to a low forecast ROE caused by the expected decline in FY23 profit and a lower Price Earnings Ratio (PER) compared to peers. **Need to ramp up growth businesses quickly.**
 - A stabilization of business performance enables balance sheet operations cognizant of capital efficiency.

Policies and targets

- Aim to achieve Medium-Term Management Plan financial targets. (FY25: ROE 8%+, Operating margin 10%+, Revenue ¥700.0B)
- Advance both growth investment (strategic investments, R&D, capex) and shareholder returns, based on the direction for capital allocation in the Medium-Term Management Plan.

Implementation of initiatives


- Implement measures aimed at recovering business performance in FY24.

 (Launch new products in mirrorless cameras and semiconductor ArF immersion lithography systems, etc.)
- Enhance information disclosure on growth businesses.

 (Plan to explain the Healthcare and Digital Manufacturing Businesses at IR Day in September)
- Officer compensation system tied to ROE and other financial KPIs. (In effect since FY22)
- Promote a growth strategy integrated with our sustainability strategy. Maintain our industry-leading ESG ratings.
- Grow dividends to reach our target of ¥60 DPS in FY25. (FY22 dividend: up ¥5 to ¥45. FY23 dividend: ¥50 planned)
- Opportunistically buyback shares of ¥30.0B+ during period of our Medium-Term Management Plan.

Financial target of the Medium-Term Management Plan: In FY25, revenue ¥ 700.0B, operating margin 10%+, ROE 8%+






Note: Amounts in this statement are rounded down to the hundred millions of yen.

Capital Allocation: Promote both investment in sustained growth and strengthening of shareholder returns





Shareholder Returns Policy in the period of the Medium-Term Management Plan



	FY21	FY22	FY23	FY24	FY25
		Med	ium-Term Manag	gement Plan (4 y	ears)
		Up ¥5 in year-end vs. previous forecast	¥ 50 planned		¥ 60 target
Dividend per share	Year-end ¥ 20 Interim ¥ 20	Year-end ¥ 25 Interim ¥ 20	Year-end ¥ 25 Interim ¥ 25	Annual ¥ 50-60	Annual ¥ 60
Share buyback		Done ¥30.0B (approx. 5.7% of outstanding shares)		share buyback of of our Medium-Te lan	
Strategic investments		SLM acquisition Approx. ¥88.0B	Consid	deration continuo	ously

Officer compensation system aimed at enhancing corporate value



System of officer compensation linked to business performance in effect since the first year of our Medium-Term Management Plan (FY22)

- The officer compensation system focuses on links to sustainable improvement in corporate value.
- ▶ The ratio of fixed compensation to performance-based compensation ranges from 1:1 to 1:1.375, depending on position.

Compensation mix and main KPIs

	Fixed compensation	Performance-based compensation					
The case of CEO	Monthly fixed compensation	Short-term business performance	Medium-term business performance	Long-term business performance			
	compensation	Bonus	Performance Stock Unit (PSU)	Restricted Stock (RS)			
Ratio of compensation	1	0.7	0.225	0.45			
Linked KPI	-	"Consolidated operating profit (OP) amount" "ROE"	Medium-Term Management Plan priorities: "OP amount from growth drivers(*1)", "OP amount from service and components", and Achievement of KPIs related to "sustainability strategy", "human capital management"	(Assignment restrictions until retirement)			
Range of link	-	0-200%	0-150%	Linked to stock price			
Distribution method		Cash Stocks					
Malus and clawback (*2)			Applies				

^(*1) Growth drivers comprise the following 5 fields: Optical and EUV related components; Material Processing and Robot Vision; Digital lithography; Imaging contents; and Contract Cell Development and Manufacturing and Drug Discovery Support.

^(*2) Malus: A clause that allows for the reduction or cancellation of vested incentive compensation before its payment if fraud or misconduct by the officer is identified. Clawback: A clause to have paid compensation returned in situations similar to the above.

Sustainability Strategy aimed at enhancing corporate value



Our corporate philosophy "Trustworthiness and Creativity"

Meet society's expectations to win "Trust"

Contribute to society through "Creativity"

Contribute to society through Creativity

Meet society's expectations to win Trust

Materialities

(1) Creating social value Industry through core technologies **Businesses** (2) Ensuring trustworthiness by maintaining and increasing quality Activity (3) Promoting a decarbonized society (4) Promoting resource circulation (5) Preventing pollution and Environment conserving ecosystems

(6) Building a resilient supply chain Respecting human rights (8) Diversity, Equity and Inclusion Society and labor (9) Employees' Health and safety (10) Thorough compliance

Quality of Life

(11) Strengthening corporate governance (12) Strengthening risk management

- FY22: **reduced by 30%** green-house gas emissions from business facilities (vs. FY13. FY25 target: 46.5%)
- Plan to migrate to 100% renewable energy beginning FY23 at core production plants in Thailand and Tochigi
- Established a **Nikon Global DEI Policy** to be deployed globally to achieve management that leverages diversity
- In FY22, **32% of new grad hires were women** (vs. 25% target). Focus on achieving 8% of management positions held by women in FY25.

Governance

Solid progress toward targets for the sustainability strategy under the Medium-term **Management Plan**

Maintain high external evaluation

Acquired top global score of its industrial group at DJSI. Received an MSCI ESG Rating of AAA.

CDP	Dow Jones	Sustainalytics		ESG investment by GPIF					
Climate Change (UK)	Sustainability Indices (DJSI) (Switzerland, US) World	(Netherlands) ESG risk score (Low risk: 20.0 or lower)	MSCI ESG Ratings (US)	MSCI Japan ESG Select Leaders Index	MSCI Japan Empowering Women Index (WIN)	S&P/JPX Carbon Efficient Index	FTSE Blossom Japan Index	FTSE Blossom Japan Sector Relative Index	
Α	In	15.9	AAA	In	In	In	In	In	



1. Action to implement management that is conscious of cost of capital and stock price

2. Financial results for the year ended March 31, 2023

3. Forecast for the year ending March 31, 2024

Summary for the year ended March 31, 2023



Revenue ¥ 628.1B

YoY: Up ¥88.5B (Down ¥1.9B vs. previous forecast)

- Revenue grew substantially in all segments but the Precision Equipment Business.
- In the Imaging Products Business, revenue grew on higher ASP due to a weaker yen and shift to mid/high-end models.
- In the Healthcare Business, revenues grew in Life Science Solutions (biological microscopes) and Eye Care Solutions (retinal diagnostic imaging systems).
- In the Components Business, revenues grew in EUV related components and optical parts and optical components.

Operating profit ¥ 54.9B

• YoY: Up ¥5.0B (Down ¥0.1B vs. previous forecast)

- Profit grew in all segments but the Precision Equipment Business. Notably, profit grew substantially in the Imaging Products and the Healthcare Businesses thanks to a weaker yen.
- Total profit grew just ¥5.0B on the substantial decline in profits in the FPD Lithography Business and increased corporate expenses.

Profit attributable to owners of parent ¥44.9B

• YoY: Up ¥ 2.3B (Up ¥ 2.9B vs. previous forecast)

Shareholder returns

- Annual dividend ¥45: Interim ¥20, Year-end ¥25 (Up ¥5 vs. previous forecast)
- Share buyback: Done ¥30.0B
- Cancellation of shares: all the repurchased stock above (21.45M shares) plus 5.00M shares of treasury stock

The year ended March 31, 2023: Financial Highlights



	FY2022/3	Previous Forecast	FY2023/3	Chai		Chan	_
Billions of Yen	Actual (A)	(Feb. 9) (B)	Actual (C)	Amount (C)-(A)	% (C)/(A)	Amount (C)-(B)	% (C)/(B)
Revenue	539.6	630.0	628.1	+88.5	+16.4%	-1.9	-0.3%
Operating profit % vs Revenue	49.9 9.3%	55.0 8.7%	54.9 8.7%	+5.0	+10.0%	-0.1	-0.2%
Profit before tax	57.0	57.0	57.0	±0.0	-0.1%	±0.0	+0.1%
% vs Revenue	10.6%	9.0%	9.1%				
Profit attributable to owners of parent	42.6	42.0	44.9	+2.3	+5.3%	+2.9	+7.0%
% vs Revenue	7.9%	6.7%	7.2%				
ROE	7.5%	7.0%	7.4%	-0.1P	-	+0.4P	-
FCF	30.9	-	-112.1	-143.0	-	-	-
Annual Dividends	¥40	¥40	¥45	+¥5	-	+¥5	-
Exchange Rate:	¥112	¥135	¥135		Impact on		
US\$	T116	+155	+155	+49		+1.	0
EURO	¥131	¥139	¥141	+14	Impact on Op 4.7	erating profit -0.	5

Revenue, operating profit and profit attributable to owners of parent grew YoY.

Substantial negative FCF due to SLM acquisition.

The year ended March 31, 2023: Performance by Segment




		FY2022/3	Previous	FY2023/3	Char	nge	Chai	nge
			Forecast		Amount	%	Amount	%
Billions of Yer	1	Actual (A)	(Feb. 9) (B)	Actual (C)	(C)-(A)	(C)/(A)	(C)-(B)	(C)/(B)
Imaging Products Business	Revenue Operating profit % vs Revenue	178.2 19.0 _{10.7%}	230.0 42.0 _{18.3%}	227.1 42.2 _{18.6%}	+48.9 +23.2 +7.9P	+27.4% +121.4%	-2.9 +0.2 +0.3P	-1.3% +0.5%
Precision Equipment Business	Revenue Operating profit % vs Revenue	211.2 39.4 _{18.7%}	210.0 24.0 _{11.4%}	203.2 24.3 _{12.0%}	-8.0 -15.1 -6.7P	-3.8% -38.2%	-6.8 +0.3 +0.6P	-3.2% +1.6%
Healthcare Business	Revenue Operating profit % vs Revenue	73.2 4.3 6.0%	93.0 8.0 8.6%	99.3 11.5 _{11.7%}	+26.1 +7.2 +5.7P	+35.7% +164.1%	+6.3 +3.5 +3.1P	+6.9% +44.8%
Components Business	Revenue Operating profit % vs Revenue	40.8 12.7 31.1%	53.0 18.0 _{34.0%}	53.9 14.6 ^{27.2%}	+13.1 +1.9 -3.9P	+32.0% +15.3%	+0.9 -3.4 -6.8P	+1.8% -18.5%
Industrial Metrology and Others	Revenue Operating profit % vs Revenue	36.0 2.9 8.2%	44.0 3.5 8.0%	44.3 3.6 8.2%	+8.3 +0.7 ±0.0P	+23.1% +22.4%	+0.3 +0.1 +0.2P	+0.9% +3.6%
Corporate expenses, etc.	Operating profit	-28.6	-40.5	-41.5	-12.9	-	-1.0	-
Consolidated	Revenue Operating profit % vs Revenue	539.6 49.9 _{9.3%}	630.0 55.0 8.7%	628.1 54.9 8.7%	+88.5 +5.0 -0.6P	+16.4% +10.0%	-1.9 -0.1 ±0.0P	-0.3% -0.2%

Note: The name of "Corporate P/L non-attributable to any reportable segment" is changed to "Corporate expenses, etc.".

In FY2023/3, "Next Generation Project Div." is transferred from Precision Equipment Business to "Corporate expenses, etc.", and retroactively applied to the FY2022/3.

The year ended March 31, 2023: Imaging Products Business





Digital Camera-Interchangeable Lens type (units: 1,000)								
Market Scale	5,120	5,800	5,810					
Nikon	700	700	700					
Interchangeable	Interchangeable Lens (units:1,000)							
Market Scale	9,390	9,800	9,400					
Nikon	1,270	1,150	1,160					
Compact DSC (u	ınits:1,000)							
Market Scale	2,720	2,000	1,990					
Nikon	190	100	110					

Revenue: Up ¥48.9B YoY (Down ¥2.9B vs. previous forecast)

- Parts procurement constraints were resolved and the market for digital cameras-interchangeable lens type grew.
- Nikon advanced its shift to mirrorless cameras and interchangeable lenses for mirrorless cameras.
- Focused on mid/high-end cameras targeting pro/hobbyists and ASP grew.
- Revenue grew with help from a weaker yen.


Operating Profit: Up ¥23.2B YoY (Up ¥0.2B vs. previous forecast)

- Profit grew substantially on increased sales volumes of mid/highend cameras, higher ASP and a weaker yen.

Note: Compact DSC: A camera equipped with uncatchable lens and do not have the function to replace lenses. (Eligible products of Nikon: COOLPIX P1000, P950, etc.)

The year ended March 31, 2023: Precision Equipment Business





• Revenue: Down ¥8.0B YoY (Down ¥6.8B vs. previous forecast)

- FPD lithography system revenue declined on lower sales volumes compared to last year, due to reduced customer capex resulting from falling panel prices.
- Semiconductor lithography system revenue grew YoY on increased sales volumes of mainly new ArF lithography systems.
- Compared to the previous forecast, we missed plan mainly because one ArF immersion lithography system was delayed into the following year.


• Operating profit: Down ¥15.1B YoY (Up ¥0.3B vs. previous forecast)

 Compared to last year, total profit in the Precision Equipment Business declined on reduced sales volumes in FPD lithography systems, despite increased sales volumes in semiconductor lithography systems.

Note: In FY2023/3, "Next Generation Project Div." is transferred from Precision Equipment Business to "Corporate expenses, etc.", and retroactively applied to the FY2022/3.

The year ended March 31, 2023: Healthcare Business





Revenue: Up ¥26.1B YoY (Up ¥6.3B vs. previous forecast)


- In Life Science Solutions (biological microscopes), we made progress expanding sales of new products and in the private sector markets mainly in North America, but also in China and other regions.
- In Eye Care Solutions (retinal diagnostic imaging systems), we won large-scale orders in North America and increased sales in Asia.
- Revenue grew substantially with help from a weaker yen.
- Compared to the previous forecast, revenues beat substantially thanks to minimized impact from parts and logistics constraints.

Operating Profit: Up ¥7.2B YoY (Up ¥3.5B vs. previous forecast)

- Profit grew substantially on increased revenues in Life Science Solutions and Eye Care Solutions and a weaker yen.

The year ended March 31, 2023: Components Business





• Revenue: Up ¥13.1B YoY (Up ¥0.9B vs. previous forecast)

- EUV related components, optical parts and optical components for semiconductor-related products and photomask substrates for FPD contributed to increased revenues.

Operating profit: Up ¥1.9B YoY (Down ¥3.4B vs. previous forecast)


- Profit grew YoY on increased revenues from sales expansion.
- Mostly in line with previous forecast, excluding the ¥3.9B impairment losses of Morf3D.
- Morf3D is our US subsidiary in contract processing for additive manufacturing. Transferred to the Digital Manufacturing Business beginning April 2023.

(See slide 29 for background to the impairment losses.)

^{*} Impairment losses of Morf3D

The year ended March 31, 2023: Industrial Metrology and Others





• Revenue: Up ¥8.3B YoY (Up ¥0.3B vs. previous forecast)

- In the Industrial Metrology Business, revenue grew YoY on solid sales of video measuring systems and X-ray and CT systems, etc.
- Revenue grew YoY on newly consolidated SLM included under the "Others".
- *SLM was transferred to the Digital Manufacturing Business beginning FY2023.

• Operating Profit: Up ¥0.7B YoY (Up ¥0.1B vs. previous forecast)

- In the Industrial Metrology Business, profit grew on increased revenues.
- Profit grew at domestic production subsidiaries included under the "Others".
- The depreciation cost of intangible assets obtained by the SLM acquisition was booked only for the three months from Jan to Mar 2023. (See slide 29 for the depreciation cost of intangible assets and others obtained by the SLM acquisition.)



1. Action to implement management that is conscious of cost of capital and stock price

2. Financial results for the year ended March 31, 2023

3. Forecast for the year ending March 31, 2024

Summary for forecast for the year ending March 31, 2024



Revenue ¥ 665.0B

Company total forecast: Up ¥36.9B YoY

- The Imaging Products Business revenue to grow on increased sales volumes of mirrorless cameras.
- The Precision Equipment Business revenue to grow as revenue growth in the Semiconductor Lithography Business outstrips the decline in the FPD Lithography Business.
- The Digital Manufacturing Business revenue to grow on full-year contribution from SLM, which became a consolidated subsidiary last fiscal year.

Operating Profit ¥43.0B

• Company total forecast: Down ¥11.9B YoY

- The Imaging Products Business to maintain high margins even as market normalization and dissipating effects of a weaker yen drive profits lower.
- The Precision Equipment Business profit to decline as increased profit in the Semiconductor Lithography Business is unable to absorb the decline in the FPD Lithography Business.
- The Healthcare Business and the Components Business see strength from continued business expansion momentum.
- The newly established Digital Manufacturing Business will start with an operating loss under the burden of depreciation resulting from the SLM acquisition and R&D expenditures.

Profit attributable to owners of parent ¥35.0B

• Company total forecast: Down ¥9.9B YoY

Shareholder returns

• Annual dividend planned: ¥50, up ¥5 YoY (interim ¥25, year-end ¥25)

Exchange rate

• US\$ ¥130, EURO ¥140

Forecast for the year ending March 31, 2024: Financial Highlights



	FY2023/3	FY2024/3		inge
Billions of Yen	Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)
Revenue	628.1	665.0	+36.9	+5.9%
Operating profit % vs Revenue	54.9 8.7%	43.0 6.5%	-11.9	-21.7%
Profit before tax	57.0	46.0	-11.0	-19.4%
% vs Revenue Profit attributable to	9.1%	6.9%		
owners of parent	44.9	35.0	-9.9	-22.1%
% vs Revenue	7.2%	5.3%		
ROE	7.4%	5.6%	-1.8P	-
EPS	¥125.46	¥101.11	-¥24.35	-
Annual Dividends	¥45	¥50	+¥5	-
Exchange Rate:	¥135	¥130	•	Revenue
US\$	1100	1 200		0.1
EURO	¥141	¥140		perating profit

Note: EPS (Basic Earnings per Share) = Profit attributable to owners of parent / Average number of shares during the term. (EPS is calculated by approx. 358M shares for FY2023/3 actual and approx. 346M shares for FY2024/3 forecast.)

Revision of reporting business segments



Old Segment	Business Unit (BU)				Busin	ess Unit (BU)	New Segment	
Imaging Products	Imaging BU				Imaging BU		Imaging Products	
Precision	FPD Lithography BU		<u> </u>		Precision	FPD Lithography BU	Duration	
Equipment	Semiconducto	r Lithography BU			Equipment Group	Semiconductor	Precision Equipment	
Healthcare	Healthcare BU				Стоир	Lithography BU	-qaipinent	
	Customized Pr	oducts BU			Healthcare BU		Healthcare	
	Glass BU				Customized Pr	oducts BU		
Components	Digital	Optical components, etc.			Glass BU		Components	
	Solutions BU	Material processing (incl. Morf3D)		1	Digital Solutions BU			
Industrial	Industrial Met	rology BU			Industrial Met	rology BU	Digital	
Metrology and	Others		 		Advanced Man	ufacturing BU	Manufacturing	
Others	SLM				Others*		Others	
Corporate	Headquarters division of the parent company				Headquarters company	division of the parent	Corporate	
expenses, etc.		Next Generation Project Division	(partly)			Next Generation Project Division	expenses, etc.	

Departments and subsidiaries in the Material Processing Business have been consolidated under the Advanced Manufacturing BU and combined with the Industrial Metrology BU to make up the Digital Manufacturing Business segment (aligns with Medium-Term Management Plan business domain).

^{*}From FY2024/3, domestic production subsidiaries under the Precision Equipment Business have been transferred to the Production Division included under the Others segment

Forecast for the year ending March 31, 2024: Forecast by Segment (New Segment)




		FY2022/3	FY2024/3	Cha	nge
Billions of Yer	1	Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)
Imaging Products Business	Revenue Operating profit % vs Revenue	227.1 42.2 _{18.6%}	240.0 38.0 _{15.8%}	+12.9 -4.2 -2.8P	+5.7% -10.0%
Precision Equipment Business	Revenue Operating profit % vs Revenue	203.2 24.5 _{12.1%}	210.0 15.0 7.1%	+6.8 -9.5 -5.0P	+3.3% -38.9%
Healthcare Business	Revenue Operating profit % vs Revenue	99.3 11.5 _{11.7%}	95.0 11.0 _{11.6%}	-4.3 -0.5 -0.1P	-4.4% -5.0%
Components Business	Revenue Operating profit % vs Revenue	53.0 22.0 _{41.6%}	53.0 20.0 37.7%	±0.0 -2.0 -3.9P	-0.1% -9.4%
Digital Manufacturing Business	Revenue Operating profit % vs Revenue	42.0 -10.1 -24.1%	64.0 -9.0 -14.1%	+22.0 +1.1 +10.0P	+52.1% -
Others (incl. Corporate expenses, etc.)	Revenue Operating profit	3.2 -35.3	3.0 -32.0	-0.2 +3.3	-7.1% -
Consolidated	Revenue Operating profit % vs Revenue	628.1 54.9 8.7%	665.0 43.0 _{6.5%}	+36.9 -11.9 -2.2P	+5.9% -21.7%

Note: FY2022/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2024: Imaging Products Business





Digital Camera-Interchangeable Lens type (units: 1,000)

Market Scale	5,810	5,500
Nikon	700	700
Interchangeable L		
Market Scale	9,200	
Nikon	1,160	1,150


• Revenue: Up ¥12.9B YoY

- Forecast continued contraction in entry level models in the market for digital camera-interchangeable lens type.
- Nikon will continue its focus on shifting toward mid/high-end cameras.
- Expect increased sales volumes of mirrorless cameras and interchangeable lenses for mirrorless cameras with the launch of new products, such as the Z 8.
- Revenue to grow on improved product mix and higher ASP.

Operating Profit: Down ¥4.2B YoY


- Profit to decline on increased expenses, such as higher sales promotion expenses in response to the resolution of parts procurement constraints and market normalization.
- Projecting the benefits of a weaker yen to dissipate.
- Expecting operating margin in the 15% range, which beats assumptions in our Medium-Term Management Plan.

Semiconductor manufacturing process and Nikon products



Forecast for the year ending March 31, 2024: Precision Equipment Business





• Revenue: Up ¥6.8B YoY

- FPD lithography system revenue to decline on substantial decrease in sales volumes due to delays in customer capex.
- Semiconductor lithography system revenue to grow on expanded sales to customers other than our core customer despite lull in demand for capex.
- The total Precision Equipment Business revenue to grow despite lower revenue in service business due to stagnant market condition.


Operating Profit: Down ¥9.5B YoY

- FPD lithography system profit to decline substantially on lower sales volumes.
- Semiconductor lithography system profit to grow on increased sales volumes of ArF lithography systems.
- The total Precision Equipment Business profit to decline as increased profit in the Semiconductor Lithography Business will be unable to absorb the decline in the FPD Lithography Business.

Note: FY2022/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2024: Healthcare Business





Revenue: Down ¥4.3B YoY


- In Life Science Solutions (biological microscopes), we expect sales expansion mainly in North America and China on development of the private sector market and strengthening of drug discovery support and solutions.
- In Eye Care Solutions (retinal diagnostic imaging systems), we expect revenue to decline despite stable growth in retinal diagnostic imaging systems as the effects of last year's major deals disappear.
- Despite overall strength, revenue to decline moderately as the effects of a weaker yen dissipate.

Operating Profit: Down ¥0.5B YoY

- Profit to remain at same level, except for the effects of weaker yen dissipation.

Forecast for the year ending March 31, 2024: Components Business





Revenue: Same level YoY

- Strength in EUV related components.
- Sales of optical parts and optical components to remain solid on continued strength in demand despite adjustment phase in semiconductor market.
- The total business flat due to lower revenues for customized orders outside of semiconductor related fields.


Operating profit: Down ¥2.0B YoY

- Profit to decline in semiconductor related fields, impacted by a lull in the collection of upfront investment in some component products to enter mass production phase.
- The total Components Business to maintain high operating margin north of 35%.

Note: FY2022/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2024: Digital Manufacturing Business





Revenue:

- A new segment comprising the Industrial Metrology BU and the newly formed Advanced Manufacturing (ADM) BU.
- The Industrial Metrology Business revenue to grow on expanded sales of video measuring systems and X-ray and CT systems, etc.
- Started* procedures for the acquisition of Avonix Imaging LLC (US) to strengthen development, manufacturing and sales in our X-ray business.
- Total segment revenue to reach ¥64.0B with the full-year contribution from SLM, which was acquired last fiscal year.

Operating profit:

- The Industrial Metrology Business profit to decline modestly YoY due to upfront investments and a one-time spike in materials costs, despite profit growth from increased sales.
- Operating profit in the ADM Business will be loss on the impact of upfront investments such as R&D costs, one-time costs associated with setting up the new BU, and the depreciation cost of intangible assets obtained by the SLM acquisition (approx. -¥3.6B).
- The total Digital Manufacturing Business will make an operating loss.


Note: FY2022/3 results have been re-stated to reflect segmentation changes.

^{*}Pending acquisition of necessary permits and licenses and satisfaction of closing terms & conditions.

Digital Manufacturing Business



Digital Manufacturing Business Operating Profit Breakdown



Note: The depreciation cost of intangible assets obtained by the SLM acquisition is booked only for the three months from Jan to Mar 2023 in FY2023/3 actual.

Impairment losses of Morf3D (-¥3.9B)

- Reviewing the position of Morf3D in its overall ADM business strategy.
- In addition to the existing contract processing business, planning to utilize Morf3D's capabilities and various licenses in the aerospace, aviation, defense, and other fields to develop additional processing applications.
- Reevaluated the value of the company's assets and posted an impairment losses on fixed assets, goodwill, etc.

SLM acquisition PPA

- Acquisition price: ¥81.2B. (92.38% ownership stake)
- In Jan23, booked ¥33.6B in intangible assets and ¥47.7B in goodwill.

Account content of asset		Amount	Depreciation years
Todaya:bla assata	Technological assets	¥33.1B	10
Intangible assets	Customer-related assets	¥0.4B	1
G	oodwill	¥47.7B	

Note: FX rate is ¥141.47/EURO

SLM standalone business performance

(from the disclosures as of March 23 as a publicity-traded company in Germany)

- EBITDA for FY 2022 (Jan-Dec) of -7.8M EURO. On a quarterly basis, SLM posted 3 consecutive quarters of positive operational profitability except for 1 quarter (2022 Jan-Mar), excluding expenses related to Nikon takeover.
- -Outlook for FY23: The Management Board expects a significantly improved EBITDA for FY23. Dirk Ackermann, CFO of SLM: "Having already achieved break-even profitability on a quarterly basis, we now look forward to further improving our operational profitability in FY23."

SLM PMI is progressing well. Aim to quickly make the Digital Manufacturing Business profitable.



Reference Data

Business segments and major products



Segments	Description		M	lajor products	
Imaging Products Business	Digital camera-interchangeable lens type Interchangeable lens Compact DSC	Mirrorless Camera [Z 8]	Mirrorless Camera [Z 30]	[NIKKOR] Lens	[NIKKOR Z DX12-28mm f/3.5-5.6 PZ VR]
Precision Equipment Business	FPD lithography system Semiconductor lithography system Alignment station Measuring & inspection system			mmersion Scanner [NSR-5635E] Alignment St. [Litho Boos	
Healthcare Business	Biological microscope Retinal diagnostic imaging system Contract Cell Manufacturing business		croscope System	Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone.]	Contract Cell Manufacturing
Components Business	EUV related component Optical parts, Optical components Encoders and Actuators Photomask substrate for FPD	Optical Parts		rn Absolute Encoder MAR-M50A] Intelligent actuator units [C3 eMotion]	Photomask Substrates for FPD
Digital Manufactur- ing Business	Metal 3D printer Optical processing machine and Contract material processing Measuring instrument X-ray system Industrial microscopy	Metal 3D Printer [NXG XII 600]	Optical Processing Machine [Lasermeister 102A]	Video Measuring System [NEXIV VMZ-S Series]	Nikon Laser Radar Measuring System [APDIS]

The year ended March 31, 2023: Financial Highlights



	FY2020/3	FY2021/3	FY2022/3				FY2023/3			
Billions of Yen	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year		
Revenue	591.0	451.2	273.0	266.6	539.6	288.3	339.8	628.1		
Operating profit % vs Revenue	6.7 1.1%	-56.2 -12.5%	32.1 11.8%	17.8 6.7%	49.9 9.3%	24.4 8.5%	30.5 9.0%	54.9 8.7%		
Profit before tax	11.8	-45.3	35.9	21.1	57.0	26.0	31.0	57.0		
% vs Revenue	2.0%	-10.0%	13.2%	7.9%	10.6%	9.0%	9.1%	9.1%		
Profit attributable to owners of parent	7.6	-34.4	26.4	16.2	42.6	18.8	26.1	44.9		
% vs Revenue	1.3%	-7.6%	9.7%	6.1%	7.9%	6.5%	7.7%	7.2%		
EPS	¥19.93	-¥93.96		¥116.23			¥125.46			
Annual Dividends	¥40	¥20		¥40	¥40		¥40		¥45	
ROE	1.3%	-6.4%		7.5%	7.5%		7.4%			
FCF	-4.8	22.9		30.9			-112.1			
Exchange Rate: US\$ EURO	¥109 ¥121	¥106 ¥124	¥110 ¥131	¥115 ¥130	¥112 ¥131	¥134 ¥139	¥137 ¥143	¥135 ¥141		

The year ended March 31, 2023: Performance by Segment



		FY2022/3			FY2023/3			
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year	
Imaging Products	Revenue	89.2	89.0	178.2	114.5	112.6	227.1	
Business	Operating profit	12.5	6.5	19.0	22.2	20.0	42.2	
Precision Equipment	Revenue	119.2	92.0	211.2	83.3	119.9	203.2	
Business	Operating profit	27.5	11.9	39.4	6.2	18.1	24.3	
Haalthaara Business	Revenue	33.0	40.2	73.2	46.6	52.7	99.3	
Healthcare Business	Operating profit	0.9	3.4	4.3	3.6	7.9	11.5	
Components Business	Revenue	16.7	24.1	40.8	26.0	27.9	53.9	
Components Business	Operating profit	3.4	9.3	12.7	9.8	4.8	14.6	
Industrial Metrology	Revenue	14.6	21.4	36.0	17.6	26.7	44.3	
and Others	Operating profit	-1.6	4.5	2.9	1.5	2.1	3.6	
	Operating profit	-10.7	-17.9	-28.6	-19.1	-22.4	-41.5	
Corporate expenses,	Broken out: Expense related to investment in growth	-10.5	-11.3	-21.8	-10.8	-12.3	-23.1	
etc.	Broken out: Expense for administration department	-2.2	-5.7	-7.9	-7.0	-8.7	-15.7	
	Broken out: Elimination of intersegment transactions	1.9	-0.7	1.2	-1.3	-1.3	-2.6	
Consolidated	Revenue	273.0	266.6	539.6	288.3	339.8	628.1	
Consolidated	Operating profit	32.1	17.8	49.9	24.4	30.5	54.9	

Note: FY2022/3 results have been re-stated to reflect segmentation changes.

In FY2023/3, "Next Generation Project Div." is transferred from Precision Equipment Business to "Corporate expenses, etc.(expense related to investment in growth)", and retroactively applied to the FY2022/3.

The year ended March 31, 2023: Quarterly Performance by New Segment



		FY2023/3						
Billions of Yen		Q1	Q2	Q3	Q4	Full Year		
Imaging Products Business	Revenue	61.2	53.3	69.9	42.7	227.1		
imaging Froducts business	Operating profit	13.6	8.6	19.0	1.0	42.2		
Precision Equipment Business	Revenue	41.4	41.9	50.2	69.7	203.2		
Frecision Equipment business	Operating profit	3.9	2.3	8.1	10.2	24.5		
Healthcare Business	Revenue	21.7	24.9	25.5	27.2	99.3		
nealthcale busiless	Operating profit	0.8	2.8	3.6	4.3	11.5		
Components Business	Revenue	12.8	12.8	11.8	15.6	53.0		
Components Business	Operating profit	5.9	5.4	4.5	6.2	22.0		
Digital Manufacturing Business	Revenue	7.4	8.8	9.8	16.0	42.0		
Digital Manufacturing Business	Operating profit	-0.9	-1.9	-1.0	-6.3	-10.1		
Others	Revenue	0.9	0.8	0.8	0.7	3.2		
Others	Operating profit	0.7	0.3	0.0	1.6	2.6		
	Operating profit	-8.7	-8.5	-8.1	-12.7	-38.0		
	Broken out: Expense related to investment in growth	-5.0	-5.1	-5.6	-5.9	-21.6		
Corporate expenses, etc.	Broken out: Expense for administration department	-2.7	-3.1	-3.3	-4.4	-13.5		
	Broken out: Elimination of intersegment transactions	-0.9	-0.3	0.8	-2.3	-2.7		
Consolidated	Revenue	145.6	142.7	167.7	172.1	628.1		
Consolidated	Operating profit	15.3	9.1	26.2	4.3	54.9		

Note: FY2022/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2024: Financial Highlights



	FY2023/3 (A)			FY20	024/3 fored (B)	cast	Change (B)-(A)				
Billions of Yen	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year		
Revenue	288.3	339.8	628.1	335.0	330.0	665.0	+46.7	-9.8	+36.9		
Operating profit	24.4	30.5	54.9	20.0	23.0	43.0	-4.4	-7.5	-11.9		
% vs Revenue	8.5%	9.0%	8.7%	6.0%	7.0%	6.5%					
Profit before tax	26.0	31.0	57.0	22.0	24.0	46.0	-4.0	-7.0	-11.0		
% vs Revenue	9.0%	9.1%	9.1%	6.6%	7.3%	6.9%					
Profit attributable to owners of parent	18.8	26.1	44.9	17.0	18.0	35.0	-1.8	-8.1	-9.9		
% vs Revenue	6.5%	7.7%	7.1%	5.1%	5.4%	5.3%					
EPS		¥125.46		¥101.11			-¥24.35				
Annual Dividends		¥45		¥50			+¥5				
ROE	7.4%			5.6%			-1.8P				
Exchange Rate: US\$	¥134	¥137	¥135		¥130			-¥5			
EURO	¥139	¥139 ¥143 ¥141			¥140			-¥1			

Forecast for the year ending March 31, 2024: Forecast by New Segment




		FY2023/3 (A)			FY2024/3 forecast (B)			Change (B)-(A)		
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	114.5	112.6	227.1	125.0	115.0	240.0	+10.5	+2.4	+12.9
Business	Operating profit	22.2	20.0	42.2	22.0	16.0	38.0	-0.2	-4.0	-4.2
Precision Equipment	Revenue	83.3	119.9	203.2	110.0	100.0	210.0	+26.7	-19.9	+6.8
Business	Operating profit	6.2	18.3	24.5	7.0	8.0	15.0	+0.8	-10.3	-9.5
Healthcare	Revenue	46.6	52.7	99.3	45.0	50.0	95.0	-1.6	-2.7	-4.3
Business	Operating profit	3.6	7.9	11.5	4.0	7.0	11.0	+0.4	-0.9	-0.5
Components	Revenue	25.6	27.4	53.0	24.0	29.0	53.0	-1.6	+1.6	±0.0
Business	Operating profit	11.3	10.7	22.0	8.0	12.0	20.0	-3.3	+1.3	-2.0
Digital Manufacturing	Revenue	16.2	25.8	42.0	29.0	35.0	64.0	+12.8	+9.2	+22.0
Business	Operating profit	-2.8	-7.3	-10.1	-5.0	-4.0	-9.0	-2.2	+3.3	+1.1
Others	Revenue	1.7	1.5	3.2	2.0	1.0	3.0	+0.3	-0.5	-0.2
Others	Operating profit	1.0	1.6	2.6	1.0	3.0	4.0	±0.0	+1.4	+1.4
	Operating profit	-17.2	-20.8	-38.0	-17.0	-19.0	-36.0	+0.2	+1.8	+2.0
Corporate	Broken out: Expense related to investment in growth	-10.1	-11.5	-21.6	-10.0	-10.0	-20.0	+0.1	+1.5	+1.6
expenses, etc.	Broken out: Expense for administration department	-5.8	-7.7	-13.5	-7.0	-9.0	-16.0	-1.2	-1.3	-2.5
	Broken out: Elimination of intersegment transactions	-1.2	-1.5	-2.7	-	-	-	+1.2	+1.5	+2.7
Consolidated	Revenue	288.3	339.8	628.1	335.0	330.0	665.0	+46.7	-9.8	+36.9
Consolidated	Operating profit	24.4	30.5	54.9	20.0	23.0	43.0	-4.4	-7.5	-11.9

Note: FY2022/3 results have been re-stated to reflect segmentation changes.


The year ended March 31, 2023: Financial Position







LIABILITIES/ EQUITY



Note: Equity ratio is ratio of equity attributable to owners of parent to total assets.


Cash and Cash Equivalents excludes time deposits with maturities of three months or more.

Capital Expenditures, Depreciation & Amortization, and Inventories


Depreciation & amortization



CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION



BREAKDOWN OF INVENTORIES



Note: Capital expenditures include right-of-use assets.


Capital expenditures

Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination.


The year ended March 31, 2023: Revenue Breakdown







BY REGION




Note: The outside and inside circles show the breakdown of FY2023/3 revenue of ¥628.1B and FY2022/3 revenue of ¥539.6B, respectively.


Forecast for the year ending March 31, 2024: R&D Expenditures



R&D EXPENDITURES



R&D EXPENDITURES BREAKDOWN




Note: R&D expenditures includes capitalization of some development expenditure.

Due to segment revision from FY2024/3, the financial figures for FY2023/3 R&D expenditures breakdown are displayed according to the reorganized display.

Cash Flow History






Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Imaging Products Business: Sales Units



SALES IN UNITS BY PRODUCT CATEGORY




Note: Compact DSC: A camera equipped with integrated lens and do not have the function to replace lenses. (Eligible products of Nikon: COOLPIX P1000, P950, etc.)

Forecast for the year ending March 31, 2024: Precision Equipment Business Sales Units





SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)




Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of i-line and other lithography systems for non-ultra-fine type (Mini Step & Repeat Exposure System).

The unit sales of new semiconductor lithography systems are 38 units in FY2020/3, 23 units in FY2022/3, 27 units in FY2023/3, and 33 units (forecast) in FY2024/3.

Precision Equipment Business: Sales Units






Precision Equipment Business: Sales Units



SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of i-line and other lithography systems for non-ultra-fine type (Mini Step & Repeat Exposure System).

Forecast for the year ending March 31, 2024: Foreign Exchange Impact



	Exchange rate	Financial Impact from Fluctuation by 1 yen	
	FY2024/3 Forecast	Revenue	Operating Profit
US \$	¥130	Approx. ¥1.7billion	Approx. ¥0.4billion
EURO	¥140	Approx. ¥0.8billion	Approx. ¥0.3billion

Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

